Influenza vaccination, access gaps, and mRNA candidates

Clinician guidance highlights tailored conversations and a reported 2025–26 flu-vaccination gap of 38% among Black Americans versus 45.6% among white Americans. Moderna’s mFLUSIVA reportedly has FDA approval for adults 50 and older, while price, coverage, restrictions, and incomplete guidance complicate uptake; GSK’s HA/NA-targeting mRNA candidate is moving into Phase 3.